Showing 2901-2910 of 4166 results for "".
- Novartis Announces Details of TALON Global Clinical Trial in Wet AMD Comparing Brolucizumab vs Aflibercepthttps://modernod.com/news/novartis-announces-details-of-talon-global-clinical-trial-in-wet-amd-comparing-brolucizumab-vs-aflibercept/2476870/In the phase 3b TALON clinical trial, Novartis announced that the two primary endpoints are superiority for brolucizumab in treatment interval duration and noninferiority in change in visual acuity. Secondary endpoints will examine durability and anatomical outcomes, including retinal fluid resol
- MeiraGTx To Present Clinical Data from Phase 1/2 Trial of AAV-RPE65 at Upcoming Scientific Conferenceshttps://modernod.com/news/meiragtx-to-present-clinical-data-from-phase-1-2-trial-of-aav-rpe65-at-upcoming-scientific-conferences/2476861/MeiraGTx Holdings announced that clinical data updates from the company’s phase 1/2 trial of AAV-RPE65 will be presented at two upcoming medical meetings. The phase 1/2 open-label, multicenter, dose-finding trial evaluated AAV-RPE65 in patients with retinal dystrophy associated with diseas
- Staar Surgical Announces EVO ICL Clinical Program for Its 16th Annual Surgical Experts Summit in Parishttps://modernod.com/news/staar-surgical-announces-evo-icl-clinical-program-for-its-16th-annual-surgical-experts-summit-in-paris/2479541/Staar Surgical announced the EVO ICL Clinical Program, which will be presented by ophthalmic surgeons to ophthalmic surgeons at its invitation only Surgical Experts Summit, is expected to be attended by over 250 surgeons and invited clinician guests from 46 countries. The Experts Summit will be h
- Oxurion to Make a Late-Breaker Presentation of Topline THR-149 Phase 1 Clinical Data at EURETINAhttps://modernod.com/news/oxurion-to-make-a-late-breaker-presentation-of-topline-thr-149-phase-1-clinical-data-at-euretina/2476844/Oxurion NV announced that it will make a late breaking presentation covering the data from its positive phase 1 clinical study with THR-149, a potent plasma kallikrein inhibitor, in patients with diabetic macular edema (DME) at the 19th European Society of Retina Specialists (EURETINA) 2019 Congr
- BioTime Initiates Dosing in Phase 1/2a Clinical Study of OpRegen for Treatment of Dry AMDhttps://modernod.com/news/biotime-initiates-dosing-in-phase-1-2a-clinical-study-of-opregen-for-treatment-of-dry-amd/2476722/BioTime announced that it has dosed its first patient with the Orbit Subretinal Delivery System (Orbit SDS) as well as with a new thaw-and-inject formulation of OpRegen, the company’s retinal pigment epithelium (RPE) transplant therapy, in its ongoing phase 1/2a clinical study for the treatment o
- Aerie Pharmaceuticals Completes Enrollment of the Netarsudil Phase 2 Clinical Trial in Japan Ahead of Schedulehttps://modernod.com/news/aerie-pharmaceuticals-completes-enrollment-of-the-netarsudil-phase-2-clinical-trial-in-japan-ahead-of-schedule/2479568/Aerie Pharmaceuticals announced that enrollment for its phase 2 clinical trial of netarsudil ophthalmic solution in Japan is complete, a milestone reached several months earlier than previously anticipated. The first patients to enter this prospective, double-masked, multicenter, placebo-
- Clinical Study Showing Reduced Incidence of Cystoid Macular Edema with Omidria Presented at ASCRShttps://modernod.com/news/clinical-study-showing-reduced-incidence-of-cystoid-macular-edema-with-omidria-presented-at-ascrs/2476575/Omeros announced the results of a real-world clinical study showing that its FDA-approved ophthalmic drug Omidria (phenylephrine and ketorolac intraocular solution) 1% / 0.3% decreases the incidence of postoperative cystoid macular edema (CME), a sight-threatening complication of cataract surgery
- GenSight Biologics Announces Positive Data for PIONEER Phase 1/2 Clinical Trial of GS030 for the Treatment of RPhttps://modernod.com/news/gensight-biologics-announces-positive-data-for-pioneer-phase-1-2-clinical-trial-of-gs030-for-the-treatment-of-rp/2476561/GenSight Biologics announced that the independent Data Safety Monitoring Board (DSMB) completed its first safety review of the ongoing PIONEER phase 1/2 clinical trial of GS030, combining gene therapy and optogenetics for the treatment of retinitis pigmentosa. The DSMB confirmed the absence of an
- Mati Therapeutics Phase 2 Nepafenac Evolute Clinical Trial Results Show Significant Postoperative Pain Reductionhttps://modernod.com/news/mati-therapeutics-phase-2-nepafenac-evolute-clinical-trial-results-show-significant-postoperative-pain-reduction/2476558/Mati Therapeutics announced that it has completed a phase 2 clinical trial evaluating the safety and efficacy of nepafenac delivered in Mati’s proprietary Evolute sustained ocular punctal plug drug delivery platform. The trial was a multicenter, randomized, masked evaluation of Nepafenac Evolute
- New Scientific And Clinical Analyses Regarding Bausch + Lomb Surgical And Pharmaceutical Products To Be Presented ARVOhttps://modernod.com/news/new-scientific-and-clinical-analyses-regarding-bausch-lomb-surgical-and-pharmaceutical-products-to-be-presented-during-the-association-for-research-in-vision-and-ophthalmology-meeting/2476505/Bausch + Lomb announced that researchers will present the results of nine new scientific and clinical analyses involving the company’s pharmaceutical and surgical products, as well as data from the company’s Antibiotic Resistance Monitoring in Ocular MicRoorganisms (ARMOR) surveillanc